GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
Bristol Myers Faces $6.7 Billion Lawsuit After Judge Allows Key Shareholder Claims to Proceed 
USPS Expands Electric Vehicle Fleet as Nationwide Transition Accelerates 
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand 
Trump Hints at Major Autism Announcement, Raises Questions on Tylenol Link 
Johnson & Johnson is reportedly exploring the acquisition of biopharmaceutical company Intra-Cellular Therapies, according to Bloomberg News. The potential deal, valued at approximately $10 billion, could be finalized as early as this week, though discussions remain in early stages.
Intra-Cellular Therapies is renowned for Caplyta, its FDA-approved treatment for schizophrenia and bipolar disorders. Acquiring the company would bolster J&J’s neuroscience portfolio, helping mitigate revenue declines expected from upcoming patent expirations on its blockbuster drugs.
Despite the promising prospects, sources caution that negotiations may not result in a finalized agreement. Intra-Cellular’s stock surged nearly 15% last Friday, reflecting heightened investor optimism over the potential acquisition.
J&J continues to focus on high-growth therapeutic areas to strengthen its pharmaceutical division amidst growing market competition. If successful, this acquisition would align with the company's strategy to expand its innovative treatments and sustain long-term growth.
